cdk inhibitor sns (MedChemExpress)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress cdk inhibitor sns

Evaluation of CDK9 protein expression and antiproliferative activity <t>of</t> <t>SNS-032</t> and THAL-SNS-032 in breast cancer cell lines. Protein levels of CDK9 in all cell lines were analyzed by Western blot ( A ). Band quantification of CDK9 protein level referred to GAPDH as the loading control ( B ). THAL-SNS-032 EC50 obtained by MTT proliferation assays in breast cancer cell lines after 72 h of treatment ( C ). Heat map depicting the effect of different doses of THAL-SNS-032 in cell death in a breast cancer cell line panel ( D ). THAL-SNS-032 reduced cell viability more than SNS-032 in BT474, BT474-RH, BT474-TDM1R, and BT474-LAPA-R at the doses indicated (72 h). We used MTT assay ( E ). * p < 0.05; ** p < 0.01; *** p < 0.001.

Cdk Inhibitor Sns, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdk+inhibitor+sns/SNS-032/pmc09146359-160-1-6
Average 93 stars, based on 12 article reviews

cdk inhibitor sns - by Bioz Stars, 2026-10

93/100 stars

Images

1) Product Images from "Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer"

Article Title: Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer

Journal: International Journal of Molecular Sciences

doi: 10.3390/ijms23105476

Evaluation of CDK9 protein expression and antiproliferative activity of SNS-032 and THAL-SNS-032 in breast cancer cell lines. Protein levels of CDK9 in all cell lines were analyzed by Western blot ( A ). Band quantification of CDK9 protein level referred to GAPDH as the loading control ( B ). THAL-SNS-032 EC50 obtained by MTT proliferation assays in breast cancer cell lines after 72 h of treatment ( C ). Heat map depicting the effect of different doses of THAL-SNS-032 in cell death in a breast cancer cell line panel ( D ). THAL-SNS-032 reduced cell viability more than SNS-032 in BT474, BT474-RH, BT474-TDM1R, and BT474-LAPA-R at the doses indicated (72 h). We used MTT assay ( E ). * p < 0.05; ** p < 0.01; *** p < 0.001.

Figure Legend Snippet: Evaluation of CDK9 protein expression and antiproliferative activity of SNS-032 and THAL-SNS-032 in breast cancer cell lines. Protein levels of CDK9 in all cell lines were analyzed by Western blot ( A ). Band quantification of CDK9 protein level referred to GAPDH as the loading control ( B ). THAL-SNS-032 EC50 obtained by MTT proliferation assays in breast cancer cell lines after 72 h of treatment ( C ). Heat map depicting the effect of different doses of THAL-SNS-032 in cell death in a breast cancer cell line panel ( D ). THAL-SNS-032 reduced cell viability more than SNS-032 in BT474, BT474-RH, BT474-TDM1R, and BT474-LAPA-R at the doses indicated (72 h). We used MTT assay ( E ). * p < 0.05; ** p < 0.01; *** p < 0.001.

Techniques Used: Expressing, Activity Assay, Western Blot, Control, MTT Assay

Antitumoral effect of SNS-032 and THAL-SNS-032 in 3D-matrix and adhesion assays in breast cancer lines and CDKs protein level evaluation after treatments. SNS-032 or THAL-SNS-032 (100 nM) was applied for 72 h to BT474, RH, and TDM1R cells seeded in a Matrigel matrix. Results presented refer to control cells. Scale bar = 100 μm ( A ). Cell adhesion to fibronectin substrate after 24 h of exposure to SNS-032 or THAL-SNS-032 (100 nM) ( B ). Expression levels of CDK9, CDK7, CDK1, and CDK2 in BT474, RH, and TDM1R cells treated with SNS-032 and THAL-SNS-032 at the times indicated at 50 nM. Scale bar = 100 μm ( C ). * p < 0.05; ** p < 0.01; *** p < 0.001.

Figure Legend Snippet: Antitumoral effect of SNS-032 and THAL-SNS-032 in 3D-matrix and adhesion assays in breast cancer lines and CDKs protein level evaluation after treatments. SNS-032 or THAL-SNS-032 (100 nM) was applied for 72 h to BT474, RH, and TDM1R cells seeded in a Matrigel matrix. Results presented refer to control cells. Scale bar = 100 μm ( A ). Cell adhesion to fibronectin substrate after 24 h of exposure to SNS-032 or THAL-SNS-032 (100 nM) ( B ). Expression levels of CDK9, CDK7, CDK1, and CDK2 in BT474, RH, and TDM1R cells treated with SNS-032 and THAL-SNS-032 at the times indicated at 50 nM. Scale bar = 100 μm ( C ). * p < 0.05; ** p < 0.01; *** p < 0.001.

Techniques Used: Control, Expressing

Cell cycle analyses of SNS-032 and THAL-SNS-032 in BT474 and BT474-derived cell lines representative of adaptive resistance. Bar graph showing populations generated by flow cytometry in each phase of cell cycle for BT474, RH, and TDM1R cells of SNS-032 (50 nM) and THAL-SNS-032 (50 nM) for 24 h ( A ). Expression of proteins involved in cell cycle in cell lines treated with SNS-032 (50 nM) and THAL-SNS-032 (50 nM) for 24 h. GAPDH was used as a loading control ( B ). * p < 0.05.

Figure Legend Snippet: Cell cycle analyses of SNS-032 and THAL-SNS-032 in BT474 and BT474-derived cell lines representative of adaptive resistance. Bar graph showing populations generated by flow cytometry in each phase of cell cycle for BT474, RH, and TDM1R cells of SNS-032 (50 nM) and THAL-SNS-032 (50 nM) for 24 h ( A ). Expression of proteins involved in cell cycle in cell lines treated with SNS-032 (50 nM) and THAL-SNS-032 (50 nM) for 24 h. GAPDH was used as a loading control ( B ). * p < 0.05.

Techniques Used: Derivative Assay, Generated, Flow Cytometry, Expressing, Control

Apoptosis process of SNS-032 and THAL-SNS-032 in BT474 and BT474-derived cell lines representative of adaptive resistance. Cell death following SNS-032 (50 nM) or THAL-SNS-032 (50 nM) treatment after 72 h in BT474 and BT474-derived cell lines representative of adaptive resistance cell lines and resistant cell lines was evaluated by flow cytometry with annexin V and propidium iodide staining ( A ). Expression of proteins involved in cell death was evaluated by Western blot in cells lines treated at 50 nM (SNS-032 and THAL-SNS-032) for 72 h. GAPDH was used as a loading control ( B ). * p < 0.05; ** p < 0.01; *** p < 0.001.

Figure Legend Snippet: Apoptosis process of SNS-032 and THAL-SNS-032 in BT474 and BT474-derived cell lines representative of adaptive resistance. Cell death following SNS-032 (50 nM) or THAL-SNS-032 (50 nM) treatment after 72 h in BT474 and BT474-derived cell lines representative of adaptive resistance cell lines and resistant cell lines was evaluated by flow cytometry with annexin V and propidium iodide staining ( A ). Expression of proteins involved in cell death was evaluated by Western blot in cells lines treated at 50 nM (SNS-032 and THAL-SNS-032) for 72 h. GAPDH was used as a loading control ( B ). * p < 0.05; ** p < 0.01; *** p < 0.001.

Techniques Used: Derivative Assay, Flow Cytometry, Staining, Expressing, Western Blot, Control

THAL-SNS-032 therapeutic index exploration. Normal breast cancer cell line MCF10A was treated with 25, 50, and 100 nM of SNS-032 and THAL-SNS-032. Proliferation was evaluated by MTT assay after 72 h of treatment ( A ). Table summary of THAL-SNS-032 doses, frequency, and route of administration in in vivo studies ( B ). Mice engrafted with BT474 cells were treated with THAL-SNS-032 (at indicated doses, I.P.) and controls with excipient. Mean of tumor volume ± SEM at each point was represented. Day of dose administration and sacrifice are indicated in each graph ( C ). Mice weight during the in vivo experiments. Treated mice (specially 10 mg/kg and 5 mg/kg) lost weight after THAL-SNS-032 administration ( D ). Western blot showing the expression levels of CDKs in tumors treated or untreated with THAL-SNS-032 ( E ). Heat map of the dependency score obtained by DepMap to evaluate CDKs dependency after CRISPR (DepMap 21Q3 Public + Score, CERES) or RNAi (Achilles + DRIVE + Marcotte, DEMETER2) inhibition ( F ). Body map showing expression of CDK9, CDK7, CDK1, and CDK2 in normal tissues in Log2(Transcript Per Million + 1) Scale. Adapted from: GEPIA2 web server (Gene Expression Profiling Interactive Analysis. http://gepia2.cancer-pku.cn/ , accessed on 27 May 2021) ( G ). *** p < 0.001.

Figure Legend Snippet: THAL-SNS-032 therapeutic index exploration. Normal breast cancer cell line MCF10A was treated with 25, 50, and 100 nM of SNS-032 and THAL-SNS-032. Proliferation was evaluated by MTT assay after 72 h of treatment ( A ). Table summary of THAL-SNS-032 doses, frequency, and route of administration in in vivo studies ( B ). Mice engrafted with BT474 cells were treated with THAL-SNS-032 (at indicated doses, I.P.) and controls with excipient. Mean of tumor volume ± SEM at each point was represented. Day of dose administration and sacrifice are indicated in each graph ( C ). Mice weight during the in vivo experiments. Treated mice (specially 10 mg/kg and 5 mg/kg) lost weight after THAL-SNS-032 administration ( D ). Western blot showing the expression levels of CDKs in tumors treated or untreated with THAL-SNS-032 ( E ). Heat map of the dependency score obtained by DepMap to evaluate CDKs dependency after CRISPR (DepMap 21Q3 Public + Score, CERES) or RNAi (Achilles + DRIVE + Marcotte, DEMETER2) inhibition ( F ). Body map showing expression of CDK9, CDK7, CDK1, and CDK2 in normal tissues in Log2(Transcript Per Million + 1) Scale. Adapted from: GEPIA2 web server (Gene Expression Profiling Interactive Analysis. http://gepia2.cancer-pku.cn/ , accessed on 27 May 2021) ( G ). *** p < 0.001.

Techniques Used: MTT Assay, In Vivo, Western Blot, Expressing, CRISPR, Inhibition, Gene Expression

Expressing:

Article Title: Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
Article Snippet: Cells authenticity was confirmed by STR analysis at the Salamanca University Hospital (molecular biology unit).Cells authenticity was confirmed by STR analysis at the Salamanca University Hospital (molecular biology unit).. The CDK-inhibitor SNS-032 was purchased from MedChemExpress (Monmouth Junction, NJ, USA) and the CDK-PROTAC THAL-SNS-032 was purchased from Tocris Bioscience (Bio-Techne R&D Systems, S.LU, Minneapolis, MN, USA).. TDM1 (trastuzumab-emtansine) and trastuzumab were purchased from a local pharmacy.TDM1 (trastuzumab-emtansine) and trastuzumab were purchased from a local pharmacy.

Review

cdk inhibitor sns (MedChemExpress)

Structured Review

Images

1) Product Images from "Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer"

Related Articles

Expressing:

Activity Assay:

Western Blot:

Control:

MTT Assay:

Derivative Assay:

Generated:

Flow Cytometry:

Staining:

In Vivo:

CRISPR:

Inhibition:

Gene Expression:

Similar Products

Image Search Results